News
GARDP And Bugworks Evaluate The New Antibiotic Tolerability
The Global Antibiotic Research and Development Partnership- GARDP and Bugworks are working together on research to determine the safety profile of a novel class of broad-spectrum antibiotic compounds focused on treating serious illnesses caused by multi drug resistant bacteria.
Bugworks is now...
News
GSK Unveils New Logo, Branding To Mirror Improved Business
The British Big Pharma has launched an innovative rebranding, a tech-flavoured logo, and an impactful transformation for the future as GlaxoSmithKline turns GSK and eliminates its consumer unit. GSK has utilised the orange colour in its logo for a...
News
Amarin Wins Vazkepa In U.K Days After US Downsizing Plan
Amarin has earned a much-needed triumph internationally after faltering in the crucial US market. Vazkepa has been approved by the National Institute for Health and Care Excellence (NICE), the United Kingdom's pricing watchdog, for around 425,000 people with high...
News
Teva Post Lupin Deal To Launch Austedo Generic Rival In 2033
Teva can rest easy knowing that it does have a long runway free of generics—at least from two major challengers—as it focuses on the tardive dyskinesia drug Austedo for growth. Teva has settled its patent infringement action with Aurobindo...
News
Fibrogen-Astellas Anaemia Drug Evrenzo Gets NICE Backing
Despite a high-profile FDA denial, FibroGen and its collaborators have been able to expand into new markets outside of the United States with Evrenzo, a novel oral anaemia medication. Evrenzo, also called Roxadustat, has been approved for reimbursement in...
News
Drug Launch Prices Have Gone Up 20% Yearly For A Decade
As many Americans face difficult financial decisions thanks to inflation, a new study verifies what many have feared for years: drug prices are significantly higher than in the past.
According to a new report published in the Journal of the...
News
FDA Advisory Group Permits Bluebird Gene Therapy Amid Risks
Bluebird bio has persuaded an expert committee that the benefits of its gene therapy possibility, eli-cel, exceed the risks, at least in certain patients, after encountering major safety concerns from FDA reviewers. The FDA invited its Cellular, Tissue, and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read